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Abstract 
Background: To evaluate the effect of insulin treatment on the incidence and/or severity of hepatocellular carci-
noma (HCC) in a mouse model of HCC based on diabetes.
Methods: We recently reported that neonatal streptozotocin (STZ) treatment causes type 1 diabetes and subse-
quent HCC in ddY, Institute for Animal Reproduction (DIAR) mice. Newborn male DIAR mice were divided into three 
groups based on STZ and insulin (INS) treatment. STZ was subcutaneously injected (60 mg/g) into the STZ-treated 
group (DIAR-nSTZ mice, N = 13) and the STZ/insulin-treated group (DIAR-nSTZ/INS mice, N = 20). A physiologic solu-
tion was injected into the control group (DIAR-control mice, N = 8) 1.5 days after birth. Insulin was subcutaneously 
injected into the DIAR-nSTZ/INS mice according to the following protocol: 2 IU/day at 4–5 weeks of age, 3 IU/day at 
5–7 weeks of age, and 4 IU/day at 7–12 weeks of age. All mice were fed a normal diet and were subjected to physi-
ological and histopathological assessments at 12 weeks of age.
Results: DIAR-nSTZ mice had significantly lower body weight and higher blood glucose levels than DIAR-control 
mice, whereas no significant differences were observed between DIAR-nSTZ/INS mice and control mice. At 12 weeks 
of age, lower weight of paratesticular fat and higher levels of total cholesterol, triglyceride, and free fatty acids were 
observed in DIAR-nSTZ mice compared to DIAR-control mice, whereas there were no significant differences between 
DIAR-nSTZ/INS mice and DIAR-control mice. In the livers of DIAR-nSTZ mice, HCC was observed in 15% of cases, and 
dysplastic nodules were observed in 77% of cases. In the livers of DIAR-nSTZ/INS mice, HCC was observed in 39% of 
cases and dysplastic nodules were observed in 61% of cases (p = 0.011). Moreover, the average tumor size was sig-
nificantly larger in STZ/INS-treated mice than in STZ-treated mice. Immunohistochemical analysis demonstrated that 
the expression of ERK1/2, downstream substrates of insulin signaling that activate cell proliferation, was significantly 
higher in STZ/INS-treated mice compared to STZ-treated mice.
Conclusions: Insulin treatment promoted, rather than inhibited, the progression of liver carcinogenesis in DIAR-nSTZ 
mice. Hyperinsulinemia rather than hyperglycemia can accelerate the progression of HCC via insulin signaling.
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Background
Diabetes mellitus (DM) has recently become a suspected 
risk factor for several malignancies, including cancers of 
the breast, endometrium, pancreas, and liver [1–4]. The 
correlation between DM and HCC is particularly strong; 
a systematic review and meta-analysis of 26 studies con-
ducted in 2005 showed that individuals with DM had a 
2.5-fold greater risk of HCC than that in controls [4].
In general, hyperglycemia is considered to increase the 
risk of developing cancer [5]. A large European cohort 
study found that blood glucose was a significant risk fac-
tor for HCC even after adjustment for other metabolic 
risk factors [6]. In addition, hyperglycemia is reported 
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to be a significant prognostic factor for HCC [7]. Hyper-
insulinemia has also been identified as a strong and 
independent risk factor for the development of vari-
ous tumors including breast, colorectal, and pancreatic 
cancers [8–10]. Accumulating evidence suggests a caus-
ative link between hyperinsulinemia and HCC develop-
ment and progression [11]. Considering these findings, 
whether or not insulin treatment is appropriate for HCC 
patients with diabetes needs to be examined. Although 
such a question remains unanswered, insulin treatment is 
often administered for HCC patients with DM.
To evaluate the effect of insulin control of blood glu-
cose on the progression of HCC, it is essential to conduct 
studies in  vivo. However, there have been few suitable 
animal models of diabetes-based HCC. We recently 
reported that neonatal streptozotocin (STZ) treatment 
causes type 1 diabetes and subsequent HCC in ddY, Insti-
tute for Animal Reproduction (DIAR) mice [12]. In this 
DIAR-nSTZ model, dysplastic nodules were observed at 
8 weeks of age and progressed to HCC by 12–19 weeks 
of age. Because of rapid neoplastic progression based on 
diabetes in the DIAR-nSTZ model, this model is con-
sidered a promising tool for elucidating a direct link 
between DM and HCC.
In the present study, the effect of insulin treatment on 
HCC progression was examined by evaluating the inci-
dence and/or severity of HCC in the murine DIAR-nSTZ 
model with or without insulin treatment.
Methods
Animal models
This study was performed at the Institute of Animal 
Reproduction in accordance with the criteria outlined in 
the “Guide for the Care and Use of Laboratory Animals” 
prepared by the National Academy of Sciences and pub-
lished by the National Institutes of Health (NIH publica-
tion 86-23 revised 1985).
The DIAR (ddy, Institute for Animal Reproduction) 
mouse strain was established in Japan by inbreeding of 
the outbred ddy strain. The body weight and visceral fat 
weight of male and female DIAR mice are slightly higher 
than that of the ddy mice until 3 months of age and no 
symptoms of diabetes are observed.
Streptozotocin (STZ) is a beta-cell toxin that induces 
insulin deficiency and hyperglycemia typical of type 1 
DM when given in low doses to mice [13]. In the current 
study, mice were divided into three groups based on STZ 
and insulin treatment. At 1.5  days after birth, STZ was 
injected subcutaneously (60 mg/g) into the STZ-treated 
group (DIAR-nSTZ mice, N = 13) and the STZ/insulin-
treated group (DIAR-nSTZ/INS mice, N = 20), whereas 
a physiologic solution was injected into the control group 
(DIAR-control mice, N  =  8). The mice were housed 
based on the treatment group in TPX cages (Okazaki 
Sangyo Co., Tokyo, Japan) in a non-barrier-sustained ani-
mal room maintained at 23 ± 2  °C with 50 ± 10% rela-
tive humidity and a 12-h light/dark cycle. All mice were 
maintained on a normal diet (MF; Oriental Yeast Co. 
Ltd., Tokyo, Japan) and chlorinated water ad  libitum. 
Insulin  (Humalin® N; Eli Lilly and Co., Indianapolis, IN, 
USA) was injected subcutaneously into DIAR-nSTZ/INS 
mice using the following protocol: 2 IU/day at 4–5 weeks 
of age, 3  IU/day at 5–7  weeks of age, and 4  IU/day at 
7–12  weeks of age. The mice in each group were sacri-
ficed and examined at 12 weeks of age.
Histological analysis
Liver samples were fixed in 10% formalin solution, 
embedded in paraffin, cut into 5-μm thick sections, and 
then deparaffinized for histological analysis. Hematoxy-
lin and eosin staining, and azan staining for fibrosis were 
performed using standard protocols.
Immunohistochemical analysis was performed to 
investigate ERK1 and ERK2 expression. ERK1/2 are 
downstream substrates of insulin signaling that acti-
vate cell proliferation [14]. An anti-ERK1 +  ERK2 anti-
body (rabbit polyclonal; Abcam, Cambridge, UK) was 
used for immunohistochemistry. After deparaffiniza-
tion, the specimens were heated with antigen retrieval 
solution, followed by endogenous peroxidase block-
ing using 5%  H2O2 in methanol for 5 min. Non-specific 
binding was blocked by incubation in 5% bovine serum 
albumin (Sigma-Aldrich, Tokyo, Japan) and the speci-
mens were incubated overnight at 4  °C in pre-diluted 
primary antibodies. The immunoreaction was visualized 
using diaminobenzidine (DAB)-chromogen/EnVision™ 
polymer-horseradish peroxidase (K4001; Dako, Glostrup, 
Denmark and SK4100; Vector Labs, Burlingame, CA, 
USA). Sections were lightly counterstained with hema-
toxylin. A previous study has reported that ERK1/2 
translocate to the nucleus from the cytoplasm following 
activation by upstream substrates of insulin signaling. 
Therefore, we focused on the nuclear expression of ERK 
1/2 [15]. Staining intensity was scored on a three-point 
scale (−, ±, +): −, nuclear staining seen in 0–20% of 
tumor cells; ±, nuclear staining seen in 20–50% of tumor 
cells; and +, nuclear staining seen in more than 50% of 
tumor cells.
Statistical analysis
Statistical analyses were performed using the SPSS Statis-
tics version 19.0 software (SPSS Inc., Chicago, IL, USA). 
The Mann–Whitney U test was used to evaluate statisti-
cal differences in weight, laboratory data, and tumor size 
between the groups. Pearson’s Chi square test was per-
formed to compare the pathological findings and scores 
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obtained from immunohistochemical analysis. Differ-
ences were considered statistically significant at p value 
<0.05.
Results
The DIAR-nSTZ mice had significantly higher blood glu-
cose levels than the DIAR-control mice but the hyper-
glycemia improved significantly by insulin treatment 
(Fig. 1a). In the DIAR-nSTZ mice, body weight loss due 
to continuous hyperglycemic state was observed whereas 
no significant difference in body weight was observed 
between the DIAR-nSTZ/INS mice and the control mice 
(Fig.  1b). At 12  weeks of age, significantly lower parat-
esticular fat weight and higher total cholesterol, triglyc-
eride, and free fatty acid levels were recognized in the 
DIAR-nSTZ mice compared to the DIAR-control mice, 
whereas there were no significant differences between 
the DIAR-nSTZ/INS mice and the DIAR-control mice 
(Fig. 2).
Multiple tumors were macroscopically observed in the 
livers of both DIAR-nSTZ and DIAR-nSTZ/INS mice 
(Fig.  3A, B). Histologically, in the livers of the DIAR-
nSTZ mice, HCC was observed in 15% of cases and 
dysplastic nodules (DNs) were observed in 77% of cases 
(Fig. 3C, D). In the livers of DIAR-nSTZ/INS mice, HCC 
was observed in 39% of cases and DNs were observed 
in 61% of cases (Fig.  3E, F). The HCC occurrence rate 
at 12 weeks of age was significantly higher in the DIAR-
nSTZ/INS mice compared to the DIAR-nSTZ mice 
(Fig.  3G). Moreover, the average tumor size was signifi-
cantly larger in the STZ/INS-treated mice than in the 
STZ-treated mice (Fig. 3H).
All mice in the control and the STZ-treated groups sur-
vived during observation. On the other hand, the survival 
rate of the DIAR nSTZ/INS mice at 12 weeks of age was 
75%, and tended to be lower than that in the other groups Fig. 1 Changes in blood glucose levels (a) and body weight (b)
Fig. 2 Laboratory data at 12 weeks of age (a p < 0.01, b P < 0.05)
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Fig. 3 Histopathological findings in mice livers after treatment. A, B Macroscopic image of the liver of DIAR-nSTZ/INS mice. C, D Dysplastic nodules 
observed in DIAR-nSTZ mice [hematoxylin and eosin staining; C ×40, D ×100]. E, F HCC observed in DIAR-nSTZ/INS mice [hematoxylin and eosin 
staining; E ×40, F ×100]. G Comparison of pathological findings. H Comparison of maximum tumor size
Page 5 of 7Baba et al. BMC Res Notes  (2017) 10:478 
(p  =  0.51). In the livers of three mice that died after 
10 weeks of age, large HCCs were observed.
In 11/18 DIAR nSTZ/INS mice, nuclear expression 
of ERK1/2 was observed in the tumor area. In contrast, 
nuclear expression was not observed in the non-tumor 
area of either the DIAR nSTZ or the nSTZ/INS mice. 
Although nuclear expression of ERK1/2 was observed 
in a few DIAR nSTZ mice (Fig.  4C), it was significantly 
specific to the DIAR nSTZ/INS mice (Fig.  4D). The 
expression of ERK1/2 was more frequently observed in 
the livers with dysplastic nodules than in the livers with 
HCC.
Discussion
The present study has provided two important findings. 
Insulin treatment improved hyperglycemia, secondary 
weight loss, and dyslipidemia caused by hyperglycemia 
in DIAR-nSTZ mice. However, insulin treatment pro-
moted, rather than inhibited, the progression of liver 
carcinogenesis. Our results suggest that hyperinsuline-
mia rather than hyperglycemia can accelerate the pro-
gression of HCC. Furthermore, immunohistochemical 
analysis of ERK1/2 suggests that activation of insulin 
signaling may accelerate tumor progression in the hyper-
glycemic state.
Several studies have reported that insulin treatment 
is a risk factor for HCC [16–18], although other stud-
ies have shown that insulin use is not associated with 
the incidence of malignancy [19, 20]. In the clinical set-
ting, insulin treatment for HCC patients with DM is 
not uncommon. It is still unclear whether insulin treat-
ment worsens the prognosis of HCC patients because 
poor blood glucose control also worsens their prognosis. 
The aim of the present study was to investigate in  vivo, 
whether the benefit of insulin treatment overrides its 
tumor proliferating effect.
The mechanisms underlying the association between 
exogenous insulin and HCC are unclear but there are 
Fig. 4 Immunohistochemical analysis of ERK1/2 expression. A, B Tumors in DIAR-nSTZ/INS mice [A ×40, B ×100]. C Tumors in DIAR-nSTZ mice [C 
×100]. D Immunohistochemistry scoring for ERK1/2
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several possibilities. First, insulin is an important mito-
gen and stimulates cell proliferation [21]. Insulin directly 
upregulates intracellular molecules such as mitogen-
activated protein kinase, involved in cell proliferation, 
by binding to insulin receptors [22]. Indeed, the current 
study demonstrated nuclear expression of ERK1/2 was 
significantly higher in DIAR-nSTZ mice that received 
insulin treatment compared to mice without insulin treat-
ment. In addition, suppressors of intracellular insulin 
signaling, such as tensin homology deleted on chromo-
some 10 and the SH2 domain containing inositol phos-
phatase-2, are downregulated in HCC; therefore, the 
effects of insulin could be enhanced in HCC [23, 24]. 
The expression of these suppressors was not examined 
in the current study. However, our result showing higher 
expression of ERK1/2 in the tumor area compared to 
the non-tumor area is compatible with this hypothesis. 
Moreover, insulin interacts with the insulin-like growth 
factor (IGF)-1 receptor [25], resulting in the activation of 
tyrosine kinase and a cascade of intracellular responses. 
Insulin also inhibits the binding of IGF-1 to IGF-binding 
proteins, causing an increase in IGF-1 levels. The IGF sys-
tem is a potent growth regulator closely associated with 
carcinogenesis [26]. Indeed, serum IGF-I level is reported 
to be an independent predictor of recurrence and survival 
in early HCC [27]. Although we did not evaluate IGF-1 
serum levels, ERK1/2 are known to be downstream sub-
strates of IGF-1 signaling as well as insulin signaling.
The present study has several limitations. First, we did 
not assess the effect of hyperglycemia on tumor pro-
gression. This would require evaluating the effects of 
blood glucose control by antidiabetic medications other 
than insulin on the incidence and/or severity of HCC in 
DIAR-nSTZ mice. The use of metformin is reported to 
be associated with a decreased risk of cancer [28] and 
a meta-analysis of observational studies showed a 50% 
reduction in HCC incidence [17]. Second, DIAR-nSTZ is 
a chemically induced model of HCC and so we focused 
on the promotion and/or progression but not the ini-
tiation action of hyperinsulinemia. Although insulin is 
thought to work as a tumor promoter or progressor via 
its effect on cell proliferation, additional studies in other 
animal models are needed to examine the potential of 
insulin as a tumor initiator. In addition, we did not exam-
ine the relationship between insulin dose and the facilita-
tory effect on HCC development. Additional experiments 
with varying doses of insulin are needed to examine the 
dose-dependent effect.
Conclusions
Insulin treatment promoted, rather than inhibited, 
the progression of liver carcinogenesis in DIAR-nSTZ 
mice. Hyperinsulinemia rather than hyperglycemia can 
accelerate the progression of HCC via insulin signaling. 
Therefore, an alternative to insulin treatment for HCC 
patients with DM should be considered, if possible. Fur-
ther studies are necessary to evaluate the carcinogenic 
effect of hyperglycemia itself.
Abbreviations
HCC: hepatocellular carcinoma; STZ: streptozotocin; DIAR: ddY, Institute for 
Animal Reproduction; DM: diabetes mellitus; DN: dysplastic nodules; IGF: 
insulin-like growth factor.
Authors’ contributions
BH, KM and TK designed the research; BH, KM, NT, HH and TK performed the 
research; HR contributed analytic tools; BH, KM and TK analyzed the data; 
and BH and TK wrote the paper. All authors read and approved the final 
manuscript.
Author details
1 Department of Pathology and Laboratory Medicine, Institute of Biomedi-
cal Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto, 
Tokushima, Tokushima 770-8503, Japan. 2 Department of Surgery and Science, 
Graduate School of Medicine and Pharmaceutical Sciences, University of Toy-
ama, 2630 Sugitani, Toyama, Toyama 930-0194, Japan. 3 Department of Clinical 
Laboratory Medicine, The University of Tokyo, Tokyo, Japan. 4 Department 
of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical 
Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama 930-0194, 
Japan. 5 Institute for Animal Reproduction, 1103 Fukaya, Kasumigaura, Ibaraki 
300-0134, Japan. 
Acknowledgements
The authors are grateful to Tokimasa Kumada, and Yukari Inoue for technical 
and secretarial assistance.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data supporting the conclusions of this article will be provided by the 
corresponding author on reasonable request.
Consent for publication
All authors consent to publish the article.
Ethics approval and consent to participate
This study was approved by the Experimental Animal Welfare Committee in 
the Institute of Animal Reproduction (No. 2013-25).
Funding
This study was funded by Grant-in-Aid for Scientific Research (B) of Japan 
(KAKENHI No. 24390181), Grant-in-Aid for Scientific Research (C) of Japan 
(KAKENHI No. 25340121) and Grant-in-Aid for Exploratory Research of Japan 
(KAKENHI Nos. 15K15098 and 25670175).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 28 January 2016   Accepted: 31 August 2017
References
 1. Heidemann C, Boeing H, Pischon T, Nöthlings U, Joost HG, Schulze MB. 
Association of a diabetes risk score with risk of myocardial infarction, 
stroke, specific types of cancer, and mortality: a prospective study in the 
Page 7 of 7Baba et al. BMC Res Notes  (2017) 10:478 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
European Prospective Investigation into Cancer and Nutrition (EPIC)-
Potsdam cohort. Eur J Epidemiol. 2009;24:281–8.
 2. Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, Weiss NS. 
Diabetes and endometrial cancer: an evaluation of the modifying effects 
of other known risk factors. Am J Epidemiol. 2008;167:607–14.
 3. Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S, Wang K. The relationship 
between new-onset diabetes mellitus and pancreatic cancer risk: a case–
control study. Eur J Cancer. 2011;47:248–54.
 4. El-Serag HB, Hampel H, Javadi F. The association between diabetes 
and hepatocellular carcinoma: a systematic review of epidemiologic 
evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.
 5. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. 
Endocr Relat Cancer. 2009;16:1103–23.
 6. Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, 
Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström 
C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Metabolic risk factors 
and primary liver cancer in a prospective study of 578,700 adults. Int J 
Cancer. 2012;131:193–200.
 7. Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, 
Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, 
Itakura J, Takahashi Y, Izumi N. Hyperglycemia is a significant prognostic 
factor of hepatocellular carcinoma after curative therapy. World J Gastro-
enterol. 2013;19:249–57.
 8. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez 
BL, Shikany JM, Strickler HD, Vitolins MZ, Rohan TE. Repeated measures of 
serum glucose and insulin in relation to postmenopausal breast cancer. 
Int J Cancer. 2009;125:2704–10.
 9. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson 
JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, 
Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, 
and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 
2009;101:48–60.
 10. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, 
Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, 
Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hypergly-
cemia, insulin resistance, impaired pancreatic β-cell function, and risk of 
pancreatic cancer. J Natl Cancer Inst. 2013;105:1027–35.
 11. Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. 
Hyperinsulinaemia and insulin signalling in the pathogenesis and the 
clinical course of hepatocellular carcinoma. Liver Int. 2015;35:2203–17.
 12. Baba H, Tsuneyama K, Nishida T, Hatta H, Nakajima T, Nomoto K, Hayashi 
S, Miwa S, Nakanishi Y, Hokao R, Imura J. Neonatal streptozotocin treat-
ment causes type 1 diabetes and subsequent hepatocellular carcinoma 
in DIAR mice fed a normal diet. Hepatol Int. 2014;8:415–24.
 13. Li Z, Karlsson FA, Sandler S. Islet loss and alpha cell expansion in type 1 
diabetes induced by multiple low-dose streptozotocin administration in 
mice. J Endocrinol. 2000;165:93–9.
 14. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, 
Vanderbilt C, Cobb MH. MAP kinases. Chem Rev. 2001;101:2449–76.
 15. Zehorai E, Yao Z, Plotnikov A, Seger R. The subcellular localization of MEK 
and ERK—a novel nuclear translocation signal (NTS) paves a way to the 
nucleus. Mol Cell Endocrinol. 2010;314:213–20.
 16. Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata 
M. Association of exogenous insulin or sulphonylurea treatment with an 
increased incidence of hepatoma in patients with hepatitis C virus infec-
tion. Liver Int. 2010;30:479–86.
 17. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medica-
tions and the risk of hepatocellular cancer: a systematic review and meta-
analysis. Am J Gastroenterol. 2013;108:881–91 (quiz 892).
 18. Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, 
Overvad K, Roswall N, Tjonneland A, Boutron-Ruault MC, et al. Diabetes 
mellitus, insulin treatment, diabetes duration, and risk of biliary tract 
cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 
2013;24:2449–55.
 19. Kath R, Schiel R, Müller UA, Höffken K. Malignancies in patients with 
insulin-treated diabetes mellitus. J Cancer Res Clin Oncol. 2000;126:412–7.
 20. Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and can-
cer incidence in Scotland: a study from the Scottish Diabetes Research 
Network Epidemiology Group. Diabetologia. 2009;52:1755–65.
 21. Barker BE, Fanger H, Farnes P. Human mammary slices in organ culture. I. 
Method of culture and preliminary observations on the effect of insulin. 
Exp Cell Res. 1964;35:437–48.
 22. Formisano P, Oriente F, Fiory F, Caruso M, Miele C, Maitan MA, Andreozzi 
F, Vigliotta G, Condorelli G, Beguinot F. Insulin-activated protein kinase C 
beta bypasses Ras and stimulates mitogen-activated protein kinase activ-
ity and cell proliferation in muscle cells. Mol Cell Biol. 2000;20:6323–33.
 23. Yao Y, Slosberg ED, Wang L, Hibshoosh H, Zhang YJ, Xing WQ, Santella RM, 
Weinstein IB. Increased susceptibility to carcinogen-induced mammary 
tumors in MMTV-Cdc25B transgenic mice. Oncogene. 1999;18:5159–66.
 24. Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K, Tanigu-
chi E, Ando E, Takata A, Fukushima N, Koga H, Torimura T, Kojiro M, Sata M. 
Significance of glucose intolerance and SHIP2 expression in hepatocel-
lular carcinoma patients with HCV infection. Oncol Rep. 2007;18:545–52.
 25. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth 
factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colo-
rectal cancer. J Natl Cancer Inst. 2002;94:972–80.
 26. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors 
and cancer. Ann Intern Med. 1995;122:54–9.
 27. Cho EJ, Lee JH, Yoo JJ, Choi WM, Lee MJ, Cho Y, Lee DH, Lee YB, Kwon JH, 
Yu SJ, et al. Serum insulin-like growth factor-I level is an independent 
predictor of recurrence and survival in early hepatocellular carcinoma: a 
Prospective Cohort Study. Clin Cancer Res. 2013;19:4218–27.
 28. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, 
Romano D, Barchielli A, Marchionni N, Rotella CM, Mannucci E. Metformin 
and cancer occurrence in insulin-treated type 2 diabetic patients. Diabe-
tes Care. 2011;34:129–31.
